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Hypercortisolism is 1 of the most common endocrine disorders in dogs.[1](#jvim12528-bib-0001){ref-type="ref"} Approximately, 15% of spontaneous cases of hypercortisolism in dogs are due to cortisol‐secreting adrenocortical adenomas or carcinomas.[1](#jvim12528-bib-0001){ref-type="ref"} Therapeutic options for dogs with adrenocortical tumors (ATs) are limited: complete adrenalectomy of the affected adrenal gland is the treatment of choice, provided no metastases are present at the time of presentation.[2](#jvim12528-bib-0002){ref-type="ref"}, [3](#jvim12528-bib-0003){ref-type="ref"} However, surgery is not possible or successful in all cases, and tumor recurrence and metastasis occur regularly.[4](#jvim12528-bib-0004){ref-type="ref"} Options for medical management are limited to mitotane, a chemotherapeutic agent, or trilostane, which can only alleviate the clinical signs of hypercortisolism. The lack of reliable prognostic markers further complicates treatment.

A pathway with the potential to provide both therapeutic targets and prognostic markers is the phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway (Fig [1](#jvim12528-fig-0001){ref-type="fig"}). The PI3K pathway is 1 of the most frequently activated signal transduction pathways in cancers of humans, the activation of which also has been documented in ATs in humans.[5](#jvim12528-bib-0005){ref-type="ref"}, [6](#jvim12528-bib-0006){ref-type="ref"}, [7](#jvim12528-bib-0007){ref-type="ref"} Pathway activation is initiated by receptor tyrosine kinases, such as the type 1 insulin‐like growth factor (IGF) receptor (IGFR1) or dimers of the epidermal growth factor (EGF) receptor family (EGFR, ERBB2--4), and counteracted by the competitive PI3K inhibitor phosphatase and tensin homolog (PTEN). Upon activation of the PI3K pathway, phosphorylated AKT (p‐AKT) and its downstream effectors stimulate cell proliferation, survival and growth by transcriptional and posttranslational mechanisms.[5](#jvim12528-bib-0005){ref-type="ref"}

![Schematic representation of the phosphatidylinositol 3 kinase (PI3K) signaling pathway. Upon ligand binding, the epidermal growth factor receptors (EGFR and ERBB 2--4) form homo‐ and heterodimers, activating their tyrosine kinase domain. The IGF receptors (IGFR1 and IGFR2) are activated by the binding of insulin‐like growth factor (IGF) I or II. IGF actions are modulated by high affinity IGF binding proteins (IGFBP 2--6). IGFR1 and the EGF receptors relay their intracellular signal to PI3K, which converts the inactive PIP2 to the active PIP3. Phosphatase and tensin homolog (PTEN) counters PI3K action by converting PIP3 back to PIP2. PIP3 production leads to the phosphorylation of AKT to phospho‐AKT (P‐AKT), which in turn activates SGK1 and XIAP through phosphorylation, while it induces mRNA expression of target genes *ID1*,*ID2*,*SNAI1*,*SNAI2*,*BCL2L1* and *CCND1*, and inhibits mRNA expression of *TRAIL*. Through its target genes, activation of the PI3K pathway results in increased cell survival, proliferation and growth. Target genes for qPCR analysis in this study are indicated in dark gray. SGK1, serum glucocorticoid regulated kinase 1; XIAP, X‐linked inhibitor of apoptosis; *ID1,* inhibitor of differentiation 1; *ID2*, inhibitor of differentiation 2; *SNAI1*, snail; *SNAI2*, slug; *BCL2L1*, B‐cell lymphoma 2 related protein; *CCND1*, cyclin D1; *TRAIL*, tumor necrosis factor superfamily member 10.](JVIM-29-214-g001){#jvim12528-fig-0001}

The PI3K pathway contains multiple targets for therapeutic intervention, the choice of which depends on the mode of activation. In adrenocortical carcinomas (ACC) of humans, frequent overexpression of *IGF‐II* and *IGFR1* indicates IGF‐signaling as a likely mode for PI3K activation.[8](#jvim12528-bib-0008){ref-type="ref"}, [9](#jvim12528-bib-0009){ref-type="ref"}, [10](#jvim12528-bib-0010){ref-type="ref"} Selective IGFR1 kinase inhibitors thus could be of benefit, and indeed have shown antitumor effects both in cell culture studies and preclinical and early phase clinical trials in humans with ACC.[6](#jvim12528-bib-0006){ref-type="ref"}, [10](#jvim12528-bib-0010){ref-type="ref"} For EGFR‐induced PI3K pathway activation, several specific inhibitors already have been approved for clinical use in humans.[11](#jvim12528-bib-0011){ref-type="ref"} Activation of the PI3K pathway also may occur downstream of the receptors, for instance as a result of mutations in the genes encoding *PTEN* or the PI3K catalytic subunit (*PIK3CA*) or because of decreased expression of *PTEN*.[12](#jvim12528-bib-0012){ref-type="ref"}, [13](#jvim12528-bib-0013){ref-type="ref"} In these cases, single or dual inhibitors of PIK3CA and mTOR could be employed.[14](#jvim12528-bib-0014){ref-type="ref"} In a human ACC cell line, use of these compounds has resulted in decreased cell proliferation and cortisol secretion.[15](#jvim12528-bib-0015){ref-type="ref"}, [16](#jvim12528-bib-0016){ref-type="ref"}

In ACC of humans, *IGF‐II* is the most frequently and strongly overexpressed gene,[17](#jvim12528-bib-0017){ref-type="ref"}, [18](#jvim12528-bib-0018){ref-type="ref"} whereas in adenomas overexpression occurs only rarely.[18](#jvim12528-bib-0018){ref-type="ref"}, [19](#jvim12528-bib-0019){ref-type="ref"} Additionally, high *IGF‐II* expression in ACC of humans is associated with aggressive tumor behavior and increased risk of metastasis.[20](#jvim12528-bib-0020){ref-type="ref"}, [21](#jvim12528-bib-0021){ref-type="ref"} Therefore, in humans IGF‐II is a diagnostic and prognostic marker for ATs.

The aim of this study was to investigate involvement of the PI3K signaling pathway in the pathogenesis of cortisol‐secreting ATs in dogs, to identify pathway components that may hold promise as future therapeutic targets or may serve as prognostic markers. Pathway activation was evaluated by means of target gene expression analysis, whereas mRNA expression analysis and mutation analysis were used to indicate mode of activation.

Materials and Methods {#jvim12528-sec-0008}
=====================

Patient Material {#jvim12528-sec-0009}
----------------

Patient material used in this study consisted of 36 cortisol‐secreting ATs from dogs and 15 whole tissue explants of normal canine adrenal glands. All normal adrenal glands from healthy dogs were available as archived tissue for comparison with AT tissue obtained from patients. The tumor group consisted of histologically confirmed ATs from patients with clinical signs of hypercortisolism, referred to the Department of Clinical Sciences of Companion Animals of the Faculty of Veterinary Medicine in Utrecht between 2001 and 2012. The diagnosis of ACTH‐independent hypercortisolism because of a cortisol‐secreting AT was based upon (1) increased urinary corticoid‐to‐creatinine ratios, that were not suppressible with high doses of dexamethasone, (2) suppressed or undetectable basal plasma ACTH concentrations[1](#jvim12528-bib-0001){ref-type="ref"} and (3) demonstration of an AT by ultrasonography, computed tomography or both.[22](#jvim12528-bib-0022){ref-type="ref"} All dogs subsequently underwent unilateral adrenalectomy. The dogs' ages at the time of surgery ranged from 2 to 12 years (mean, 9 years). Seven dogs were mongrels and the other dogs were of 22 different breeds. Eighteen of the dogs were male (8 castrated) and 18 female (12 spayed).

After resection, all ATs and normal adrenal glands were immediately put on ice for inspection, and material was saved for quantitative RT‐PCR (qPCR) analysis and histopathology. Fragments for RNA isolation were snap frozen in liquid nitrogen within 10 minutes after resection and stored at −80°C until further use. The remaining part of the tissue was immersed in formalin for fixation and embedded in paraffin after 24--48 hours. Permission to use the AT tissue for this study was obtained from all patient owners and the study was approved by the Ethical Committee of Utrecht University.

Histopathology {#jvim12528-sec-0010}
--------------

Histopathological evaluation was performed on formalin‐fixed and paraffin‐embedded tissue slides of all samples and used to confirm the diagnosis and classify the tumors. All histological evaluations were performed by a single pathologist. Classification was performed based on criteria described previously.[23](#jvim12528-bib-0023){ref-type="ref"} Classification as a carcinoma was based on histological evidence of vascular invasion, peripheral fibrosis, capsular invasion, trabecular growth, hemorrhage, necrosis, and single cell necrosis. Typical histological characteristics of adenomas were hematopoiesis, fibrin thrombi, and cytoplasmic vacuolization. Based on these criteria, the tumor group consisted of 11 adenomas and 25 carcinomas.

Follow‐up {#jvim12528-sec-0011}
---------

Of the dogs in the tumor group, follow‐up information was available for 15 dogs with histologically confirmed carcinomas: 7 of these dogs developed signs of hypercortisolism within 2.5 years after surgical removal of the tumor. Recurrence of hypercortisolism was confirmed by endocrine testing, and was caused by metastases in 6 of these dogs, and by regrowth of the AT in 1 dog. The remaining 8 dogs were in remission for at least 2.5 years after adrenalectomy.

Total RNA Extraction and Reverse Transcription {#jvim12528-sec-0012}
----------------------------------------------

Total RNA for quantitative RT‐PCR analysis was isolated from the adrenal tissue using the RNeasy mini kit,[1](#jvim12528-note-0001){ref-type="fn"} according to manufacturer\'s protocols. An additional DNAse step was performed to avoid genomic DNA contamination. RNA concentrations were measured on the NanoDrop ND‐1000.[2](#jvim12528-note-0002){ref-type="fn"} Synthesis of cDNA was performed using the iScript cDNA synthesis kit,[3](#jvim12528-note-0003){ref-type="fn"} according to the manufacturer\'s protocols. For all samples, 1 cDNA reaction was performed without reverse transcriptase (RT−), to check for contamination with genomic DNA.

Quantitative RT‐PCR {#jvim12528-sec-0013}
-------------------

Primers for qPCR were designed to detect the mRNA expression levels of PI3K pathway target genes (Table [1](#jvim12528-tbl-0001){ref-type="table-wrap"}), PI3K pathway inhibitor PTEN and major components of the IGF and EGF axis (Table [2](#jvim12528-tbl-0002){ref-type="table-wrap"}). Primer design was performed using Perl‐primer v1.1.14 according to the parameters in the Bio‐Rad iCycler manual, and primers were ordered from Eurogentec.[4](#jvim12528-note-0004){ref-type="fn"} For all primer pairs, a temperature gradient was performed to determine the optimal annealing temperature. Formation of the proper PCR products was confirmed by a sequencing reaction, using the ABI3130XL Genetic analyzer[5](#jvim12528-note-0005){ref-type="fn"} according to the manufacturer\'s protocol.

###### 

Quantitative RT‐PCR primer pairs for the detection of PI3K target genes: *SNAI1*,*SNAI2*,*BCL2L1*,*ID1* and *ID2*,*CCND1*,*SGK11*,*TNFSF10* or *TRAIL*, and *XIAP*. All positions are based on the mRNA sequence, as published on the NCBI website

  qPCR Primers (Position)   Sequence (5′--3′)                       Annealing Temperature (°C)   Product Length (bp)
  ------------------------- --------------------------------------- ---------------------------- ---------------------
  cf_SNAI1                                                                                       
  Fw                        CAA GAT GCA CAT CCG AAG C               61.6                         133
  Rv                        CAG TGG GAG CAG GAA AAC                                              
  cf_SNAI2                                                                                       
  Fw                        CTT CAC TCC GAC TCC AAA CG              60                           148
  Rv                        TGG ATT TTG TGC TCT TGC AG                                           
  cf_BCL2L1                                                                                      
  Fw                        GGG GTG GTG AGG TAC AAA AA              61.6                         112
  Rv                        CTG GGT CTA GCG TCC AAA AG                                           
  cf_ID1                                                                                         
  Fw                        CTC AAC GGC GAG ATC AG                  59.5                         135
  Rv                        GAG CAC GGG TTC TTC TC                                               
  cf_ID2                                                                                         
  Fw                        GCT GAA TAA ATG GTG TTC GTG             60.5                         114
  Rv                        GTT GTT CTC CTT GTG AAA TGG                                          
  cf_CCND1                                                                                       
  Fw                        GCC TCG AAG ATG AAG GAG AC              60                           117
  Rv                        CAG TTT GTT CAC CAG GAG CA                                           
  cf_TNFSF10                                                                                     
  Fw                        GCT GAT CCT CAT CTT CAC TG              62                           90
  Rv                        TCC TGC ATC TGC TTC AG                                               
  cf_SGK11                                                                                       
  Fw                        TGG GCC TGA ACG ACT TTA TT              62                           124
  Rv                        GAG GGG TTG GCA TTC ATA AG                                           
  cf_XIAP                                                                                        
  Fw                        ACT ATG TAT CAC TTG AGG CTC TGG TTT C   54                           80
  Rv                        AGT CTG GCT TGA TTC ATC TTG TGT TAT G                                

Accession numbers used: *SNAI1*: [XM_543048.1](XM_543048.1); *SNAI2*: [XM_543048.1](XM_543048.1); *CDH1*: [XM_536807.3](XM_536807.3); *BCL2L1*: [NM_001003072.1](NM_001003072.1); *ID1*: [XM_847117.2](XM_847117.2); *ID2*: [XR_134413.1](XR_134413.1); *CCND1*: [NM_001005757.1](NM_001005757.1); *SGK11*: [XM_003432525.1](XM_003432525.1); *TNFSF10*: [NM_001130836](NM_001130836); *XIAP*: [XM_003435664.1](XM_003435664.1).

PI3K, phosphatidylinositol 3 kinase; *SNAI1*, snail; *SNAI2*, slug; *BCL2L1*, B‐cell lymphoma 2 related protein; *ID1* and *ID2*, inhibitor of DNA binding 1 and 2; *CCND1*, CyclinD1; *SGK11*, serum/glucocorticoid regulated kinase 1; *TNFSF10* or *TRAIL*, tumor necrosis factor superfamily member 10; *XIAP*, X‐linked inhibitor of apoptosis; Fw, forward primer; Rv, reverse primer.

John Wiley & Sons, Ltd

###### 

qPCR primer pairs for the detection of genes encoding components of the IGF‐ and EGF axis, and *PTEN*:*EGFR*,*ERBB2--4*,*PTEN*,*IGF‐I* and *IGF‐II*,*IGFR1* and *IGFR2*,*IGFBP 2--6*, and *INSR*. All positions are based on the mRNA sequence, as published on the NCBI website

  qPCR Primers (Position)   Sequence (5′--3′)                Annealing Temperature (°C)   Product Length (bp)
  ------------------------- -------------------------------- ---------------------------- ---------------------
  cf_EGFR                                                                                 
  Fw                        CTG GAG CAT TCG GCA              53                           107
  Rv                        TGG CTT TGG GAG ACG                                           
  cf_ERBB2                                                                                
  Fw                        CGT GCT GGA CAA TGG AGA CC       64                           126
  Rv                        CCG CTG AAT CAA GAC CCC TC                                    
  cf_ERBB3                                                                                
  Fw                        TAG TGG TGA AGG ACA ACG GCA G    64                           103
  Rv                        GGT CTT GGT CAA TGT CTG GCA G                                 
  cf_ERBB4                                                                                
  Fw                        CAG TTC TTG TGT GCG TGC CTG      70                           121
  Rv                        ATG ATC CTG TGC CGA TGC C                                     
  cf_PTEN                                                                                 
  Fw                        AGA TGT TAG TGA CAA TGA ACC T    62                           101
  Rv                        GTG ATT TGT GTG TGC TGA TC                                    
  cf_IGF‐I                                                                                
  Fw                        TGT CCT CCT CGC ATC TCT T        58                           125
  Rv                        GTC TCC GCA CAC GAA CTG                                       
  cf_IGF‐II                                                                               
  Fw                        CTT CTG GAG ACC TAC TGT GC       61                           128
  Rv                        CTG CTT CCA GGT GTC GTA TTG                                   
  cf_IGFR1                                                                                
  Fw                        CAT GCC TTG GTC TCC CTG T        60                           129
  Rv                        GGT GGT CCC AAT CCC AAA G                                     
  cf_IGFR2                                                                                
  Fw                        GAG TTC AGC CACG AGA C           54                           94
  Rv                        GCA TTG TCA CCA TCA AGG                                       
  cf_IGFBP2                                                                               
  Fw                        GAT CTC CAC CAT GCA CCT TC       60                           127
  Rv                        GCT GCC CGT TCA GAG ACA TCT TG                                
  cf_IGFBP3                                                                               
  Fw                        CTG CAC ACG AAG ATG GAT GT       61                           127
  Rv                        TAT TCC GTC TCC CGC TTG TA                                    
  cf_IGFBP4                                                                               
  Fw                        AGC CTG CAG CCC TCT GAC A        59                           120
  Rv                        TGG TGC TGC GGT CTC GAA T                                     
  cf_IGFBP5                                                                               
  Fw                        TCG CAG AAA GAA GCT GAC C        60                           131
  Rv                        GAA GCC TCC ATG TGT CTG C                                     
  cf_IGFBP6                                                                               
  Fw                        CAA TCC TGG TGG TGT CC           54                           136
  Rv                        AGA AGC CCT TAT GGT CAC                                       
  cf_INSR                                                                                 
  Fw                        GTG ACA GAC TAT TTA GAT GTC CC   60                           166
  Rv                        ACT CAG GGT TTG AAG AAG C                                     

Accession numbers used: *EGFR*: [XM_533073.3](XM_533073.3); *ERBB2*: [NM_001003217.1](NM_001003217.1); *ERBB3*: [XM_538226.4](XM_538226.4); *ERBB4*: [XM_003640190.2](XM_003640190.2); *PTEN*: [NM_001003192.1](NM_001003192.1); *IGF‐I*: [XM_848024.1](XM_848024.1); *IGF‐II*: [XM_858107.1](XM_858107.1); *IGFR1*: [XM_853622.1](XM_853622.1); *IGF‐IIR*: [NM_001122602](NM_001122602); *IGFBP2*: [XM_545637.2](XM_545637.2); *IGFBP3*: [XM_548740.2](XM_548740.2); *IGFBP4*: [XM_845091.1](XM_845091.1); *IGFBP5*: [XM_847792.1](XM_847792.1); *IGFBP6*: [XM_844250](XM_844250); *INSR*: [XM_542108](XM_542108).

*EGFR*, epidermal growth factor receptor; *ERBB2--4*, erythroblastic leukemia viral oncogene homolog 2--4; *PTEN*, phosphatase and tensin homolog; *IGF‐I* and *IGF‐II*, insulin‐like growth factor 1 and 2; *IGFR1* and *IGFR2*, IFG receptor type 1 and 2; *IGFBP 2--6*, IGF binding protein 2--6; *INSR,* insulin receptor; Fw, forward primer; Rv, reverse primer.

John Wiley & Sons, Ltd

For mRNA expression analysis of the EGF receptors, PI3K target genes and PTEN, a 10× diluted pool of cDNA samples was used to create a 4‐fold standard dilution series. The remaining cDNA was diluted 5 times with milliQ water, to achieve a working stock. Reactions were performed on a CFX384 real‐time PCR detection system.[3](#jvim12528-note-0003){ref-type="fn"} The following genes were measured as follows: EGF receptor (*EGFR*), erythroblastic leukemia viral oncogene homolog 2--4 (*ERBB2--4*), snail (*SNAI1*), slug (*SNAI2*), B‐cell lymphoma 2 related protein (*BCL2L1*), cyclinD1 (*CCND1*), inhibitor of differentiation 1 and 2 (*ID1* and *ID2*), tumor necrosis factor superfamily member 10 (*TNFSF10* or *TRAIL*), serum glucocorticoid regulated kinase 1 (*SGK1*), X‐linked inhibitor of apoptosis (*XIAP*) and *PTEN*. To correct for differences in cDNA concentration, ribosomal protein S5 (*RPS5*), *RPS19*, small proline rich protein (*SPRP*) and hypoxantine phosphoribosiltransferase (*HPRT*) were used as reference genes.[24](#jvim12528-bib-0024){ref-type="ref"}, [25](#jvim12528-bib-0025){ref-type="ref"}

For mRNA expression analysis of *IGF‐I*,*IGF‐II*,*IGFR1*,*IGFR2*, IGF binding proteins (*IGFBP 2--6*) and the insulin receptor (*INSR*), an undiluted pool of cDNA samples was used to create a 4‐fold standard dilution series. The remainder of the cDNA was diluted 10 times with milliQ water, to achieve a working stock. Reactions were performed on a MyIQ single color real‐time PCR detection system.[3](#jvim12528-note-0003){ref-type="fn"} To correct for differences in cDNA concentration, *RPS5*,*RPS19*,*SPRP* and beta‐glucuronidase (*GUSB*) were used as reference genes.[24](#jvim12528-bib-0024){ref-type="ref"}, [25](#jvim12528-bib-0025){ref-type="ref"}

Detection was performed using SYBRgreen supermix[3](#jvim12528-note-0003){ref-type="fn"} and data were analyzed using CFX Manager 3.0[3](#jvim12528-note-0003){ref-type="fn"} for the CFX384 real‐time PCR data and using iQ5 software[3](#jvim12528-note-0003){ref-type="fn"} for the MyIQ single color real‐time PCR data. The raw data were used to calculate the reaction efficiency. Reaction efficiencies between 90% and 110% were accepted. Analysis of the relative expression levels of the reference genes disclosed no significant differences among groups and reference gene expression was shown to be stable using GeNorm software,[21](#jvim12528-bib-0021){ref-type="ref"} justifying the use as reference genes. Calculation of normalized relative expression levels for each of the target genes was performed using the 2^−ΔΔCT^ method.[26](#jvim12528-bib-0026){ref-type="ref"}

Mutation Analysis {#jvim12528-sec-0014}
-----------------

Mutation analysis was performed on *PTEN* and *PIK3CA*. Primers for PCR amplification (Table [3](#jvim12528-tbl-0003){ref-type="table-wrap"}) and sequence primers (Table [4](#jvim12528-tbl-0004){ref-type="table-wrap"}) were designed using Perl‐primer v1.1.14 according to BioRad iCycler parameters, and ordered from Eurogentec.[4](#jvim12528-note-0004){ref-type="fn"} Sequence primers were located along the entire transcript, at a distance of 300--500 bp apart, or closer together when needed for complete coverage. Amplification primers were located in the 3′ and 5′untranslated regions (UTRs) of the gene to ensure amplification of the complete coding region. For *PTEN*, the canine 3′ UTR is not annotated and was deduced from the human 3′ UTR and the canine genomic *s*equence. If a gene could not be amplified in 1 stretch, overlapping primer pairs were used. All amplification primers were tested on a pool of adrenal samples, to determine the optimal annealing temperature. Correct product formation was evaluated by means of gel electrophoresis and sequencing.

###### 

PCR primers pairs for amplification of phosphatase and tensin homolog (*PTEN*) and phosphatidylinositol 3 kinase, catalytic subunit alpha (*PIK3CA*). All positions are based on the mRNA sequence, as published on the NCBI website

  PCR Primers (Position)   Sequence (5′--3′)            Annealing Temperature (°C)   Product Length (bp)
  ------------------------ ---------------------------- ---------------------------- ---------------------
  cf_PTEN                                                                            
  Fw75                     TCC TCC TTC CTC TCC AG       55                           748
  Rv822                    TGA ACT TGT CTT CCC GTC                                   
  Fw718                    CAA TGT TCA GTG GCG GA       55                           743
  Rv1460                   CGA GAT TGG TCA GGA AGA G                                 
  cf_PIK3CA                                                                          
  F1                       TTT CTG CTT TGG GAC AGC      55                           1536
  R1537                    CTG GGA ACT TTA CCA CAC TG                                
  Fw1438                   TGC TGA ACC CTA TTG GTG      55                           449
  Rv1887                   TAC AGT CCA GAA GCT CCA                                   
  Fw1516                   GCA GTG TGG TAA AGT TCC      55                           1843
  Rv3359                   CAG TCT TTG CCT GTT GAC                                   

Accession numbers used: *PTEN*: [NM_001003192.1](NM_001003192.1); *PIK3CA*: [XM_545208.3](XM_545208.3).

Fw, forward primer; Rv, reverse primer.

John Wiley & Sons, Ltd

###### 

Sequencing primers for the mutation analysis of phosphatase and tensin homolog (*PTEN*) and phosphatidylinositol 3 kinase, catalytic subunit alpha (*PIK3CA*). All positions are based on the mRNA sequence, as published on the NCBI website

  Sequence Primers (Position)   Sequence (5′--3′)
  ----------------------------- ----------------------------
  cf_PTEN                       
  Fw474                         CAC TGT AAA GCT GGA AAG GG
  Fw1157                        TGT AGA GGA GCC ATC AAA CC
  Rv249                         CAA AGG GTT CAT TCT CTG GG
  Rv595                         TGT CTC TGG TCC TTA CTT CC
  Rv1285                        CCT GTA TAC GCC TTC AAG TC
  cf_PIK3CA                     
  Fw375                         GTA ATT GAG CCA GTA GGC
  Fw707                         CAA CCA TGA CTG TGT TCC
  Fw1153                        TCT ATC ATG GAG GAG AAC CC
  Fw1483                        CTC CAT GCT TAG AGT TGG AG
  Fw1767                        CTA CCC AAA CTG CTT CTG
  Fw2183                        TAG GCA AGT TGA GGC TAT GG
  Fw2582                        TGG TTG TCT GTC AAT CGG
  Fw2806                        TGG GAA TTG GAG ATC GTC
  Fw2963                        GAT TAG TAA AGG AGC CCA GG
  Rv358                         AAA GCC GAA GGT CAC AAA GC
  Rv730                         GTT CTG GAA CAC AGT CAT GG
  Rv1236                        TAG CCA TTC ATT CCA CCT GG
  Rv1750                        CAC AAT AGT GTC TGT GGC TC
  Rv2205                        TTC CAT AGC CTC AAC TTG CC
  Rv2642                        GTG TGA GAA TTT CGC ACC
  Rv2993                        TTT GTG CAT TCC TGG GCT
  Rv3271                        CAT GCT GCT TAA TGG TGT GG

Accession numbers used: *PTEN*: [NM_001003192.1](NM_001003192.1); *PIK3CA*: [XM_545208.3](XM_545208.3).

Fw, forward primer; Rv, reverse primer.

John Wiley & Sons, Ltd

After PCR optimization, target genes in all samples were amplified on a C1000 Touch thermal cycler[3](#jvim12528-note-0003){ref-type="fn"} using Phusion Hot Start Flex DNA Polymerase.[6](#jvim12528-note-0006){ref-type="fn"} The PCR products were amplified for sequencing using the BigDye Terminator version 3.1 Cycle Sequencing Kit[7](#jvim12528-note-0007){ref-type="fn"} and filtrated using Sephadex G‐50 Superfine.[8](#jvim12528-note-0008){ref-type="fn"} Sequencing reactions were performed on an ABI3130XL Genetic analyzer, according to the manufacturer\'s instructions. The sequences obtained were aligned to the NCBI consensus mRNA sequence using DNAstar Lasergene core suite 9.1 SeqMan software. Mutations altering the amino acid sequence were confirmed by repeat RNA extraction and sequencing in both sense and antisense directions.

Statistical Analyses {#jvim12528-sec-0015}
--------------------

Statistical analyses were performed using SPSS20.[9](#jvim12528-note-0009){ref-type="fn"} Because of the non‐normal distribution of most of the variables, the nonparametric Mann‐Whitney *U*‐test was used to compare mRNA expression levels among groups. The relative mRNA expression levels were compared between ATs (adenomas and carcinomas) and normal adrenals and between ATs with and without recurrent disease. For the first comparison, a Bonferroni correction was applied and *P* \< .025 was considered significant, whereas for the latter comparison, a *P* \< .05 was considered significant.

Results {#jvim12528-sec-0016}
=======

Relative mRNA Expression of PI3K Target Genes {#jvim12528-sec-0017}
---------------------------------------------

To evaluate whether activation of the PI3K pathway was present in cortisol‐secreting ATs of dogs, mRNA expression analysis was performed on a selection of 10 known target genes of the pathway. Based on the literature, PI3K activation would increase mRNA expression of *ID1*,[27](#jvim12528-bib-0027){ref-type="ref"}, [28](#jvim12528-bib-0028){ref-type="ref"} *ID2*,[29](#jvim12528-bib-0029){ref-type="ref"} *SNAI1* and *SNAI2*,[30](#jvim12528-bib-0030){ref-type="ref"} *CCND1* and *BCL2L1*.[31](#jvim12528-bib-0031){ref-type="ref"} In contrast, lower mRNA expression of *TRAIL* [31](#jvim12528-bib-0031){ref-type="ref"}, [32](#jvim12528-bib-0032){ref-type="ref"} would be expected (Fig [1](#jvim12528-fig-0001){ref-type="fig"}). The activation of SGK1 and XIAP occurs by means of phosphorylation; so for these genes, no effect on mRNA expression would be expected[33](#jvim12528-bib-0033){ref-type="ref"}, [34](#jvim12528-bib-0034){ref-type="ref"} (Fig [1](#jvim12528-fig-0001){ref-type="fig"}). In ACC of dogs, the relative mRNA expression levels when compared to those in normal adrenal glands (Fig [2](#jvim12528-fig-0002){ref-type="fig"}A) were significantly higher for *ID1* (2.1‐fold, *P *=* *.021) and *SNAI1* (1.8‐fold, *P *=* *.024), and significantly lower for *SGK1* (0.5‐fold, *P *=* *.009). The relative mRNA expression of *TRAIL* (0.6‐fold, *P *=* *.028) tended to be lower. Thus, in carcinomas 3 of the 7 transcriptionally regulated target genes showed a change in accordance with pathway activation, whereas the mRNA expression of the other genes remained unchanged.

![Box‐and‐whisker plot describing the relative mRNA expression of phosphatidylinositol 3 kinase target genes in 37 canine adrenocortical tumors (ATs) and 15 normal adrenal glands, as measured by qPCR and calculated using the 2^−ΔΔCT^ method. Relative expression in adenomas and carcinomas when compared to normal adrenal glands **(A)**. Relative expression in ATs with recurrence within 2.5 years after adrenalectomy, when compared with ATs remaining in remission for at least 2.5 years **(B)**. Significant changes (*P *\<* *.05 for A and *P* \< .025 for B) are marked with an asterisk. N, normal adrenal gland; C, adrenocortical carcinoma; A, adrenocortical adenoma; *SNAI1*, snail; *SNAI2*, slug; *BCL2L1*, B‐cell lymphoma 2 related protein; *ID1* and *ID2*, inhibitor of DNA binding 1 and 2; *CCND1*, CyclinD1; *SGK11*, serum/glucocorticoid regulated kinase 1; *TNFSF1*, tumor necrosis factor superfamily member 10; *XIAP*, X‐linked inhibitor of apoptosis.](JVIM-29-214-g002){#jvim12528-fig-0002}

In adenomas, the mRNA expression of none of the genes showed a significant change consistent with PI3K pathway activation (Fig [2](#jvim12528-fig-0002){ref-type="fig"}A). The only significant finding was a lower relative expression of *CCND1* (0.42‐fold, *P *=* *.004) when compared to that of normal adrenal glands.

When comparing dogs with recurrent disease within 2.5 years to dogs remaining in remission (Fig [2](#jvim12528-fig-0002){ref-type="fig"}B), a significantly higher expression of both *ID1* (2.0‐fold, *P *=* *.033) and *ID2* (2.4‐fold, *P *=* *.019) was detected in dogs with recurrent disease. No significant changes were detected in the expression of other target genes.

Relative mRNA Expression of PTEN and the Components of IGF and EGF Signaling {#jvim12528-sec-0018}
----------------------------------------------------------------------------

To evaluate for a potential cause of PI3K activation, mRNA expression levels of the components of the IGF axis, the EGF receptors and PI3K‐inhibitor *PTEN* were evaluated. Analysis of the components of the IGF axis in carcinomas (Fig [3](#jvim12528-fig-0003){ref-type="fig"}A) disclosed a significantly higher expression of *IGFBP*2 (5.8‐fold, *P *=* *.001) and a significantly lower expression of *IGFBP5* (0.5‐fold, *P *=* *.001). Likewise, in adenomas, *IGFBP2* expression was significantly higher (7.2‐fold, *P *=* *.013) and *IGFBP5* expression was significantly lower (0.4‐fold, *P *\<* *.001). No significant differences in the expression levels of *IGF‐II* or the *IGFR1* were detected.

![Box‐and‐whisker plot describing the relative mRNA expression of genes encoding components of the IGF‐ and EGF axis, and *PTEN* in 37 canine ATs and 15 normal adrenal glands, as measured by qPCR and calculated using the 2^−ΔΔCT^ method. Relative expression in adenomas and carcinomas when compared to normal adrenal glands **(A)**. Relative expression in ATs with recurrence within 2.5 years after adrenalectomy, when compared with ATs remaining in remission for at least 2.5 years **(B)**. Significant changes (*P *\<* *.05 for A and *P *\<* *.025 for B) are marked with an asterisk. N, normal adrenal gland; C, adrenocortical carcinoma; A, adrenocortical adenoma; *PTEN*, phosphatase and tensin homolog; *IGF‐I* and 2, insulin like growth factor 1 and 2; *IGFR1*, IFG receptor type 1; *IGF‐IIR*, IGF receptor type 2; *IGFBP2--6*, IGF binding protein 1--6; *INSR*, insulin receptor; *EGFR*, epidermal growth factor receptor; *ERBB2--4*, erythroblastic leukemia viral oncogene homolog 2--4.](JVIM-29-214-g003){#jvim12528-fig-0003}

Analysis of the EGF receptors in carcinomas identified a tendency to higher *ERBB2* expression (1.7‐fold, *P *=* *.027) and significantly lower expression of *ERBB3* (0.4‐fold, *P *=* *.003). In adenomas, the only significant change was lower *ERBB3* expression (0.2‐fold, *P *=* *.001).

When comparing dogs with recurrent disease within 2.5 years to dogs remaining in remission (Fig [3](#jvim12528-fig-0003){ref-type="fig"}B), significantly higher expression of *IGF‐I* (2.7‐fold, *P *=* *.042), *IGFBP5* (6.8‐fold, *P *=* *.042) and *INSR* (2.3‐fold, *P *=* *.040) was detected.

Mutation Analysis of PTEN and PIK3CA {#jvim12528-sec-0019}
------------------------------------

To determine whether inactivating mutations of *PTEN* or activating mutations of *PIK3CA* might be responsible for activation of the PI3K pathway, mutation analysis was performed. Mutation analysis of *PTEN* identified the presence of 1 silent mutation in codon 325 (CTC\>CTT), which was present in 6 ATs and occurred in both homo‐ and hetero‐zygous form. No amino acid‐changing mutations were detected in of any of the ATs.

Mutation analysis of *PIK3CA* identified the presence of 3 different heterozygous silent mutations (codon 149 CCA\>CCC, codon 438 TCT\>TCA and codon 842 GTG\>GTT) in 3 different ATs. No amino acid‐changing mutations were detected in any of the ATs.

Discussion {#jvim12528-sec-0020}
==========

In this study, we aimed to investigate activation of the PI3K pathway in cortisol‐secreting adrenocortical adenomas and carcinomas of dogs, to identify both potential therapeutic targets and prognostic markers for use in dogs with ATs. The presence of PI3K activation was assessed by means of target gene expression analysis. In adenomas, none of the target genes showed a significant change consistent with PI3K pathway activation, and there was even a significantly lower expression of *CCND1*. This may be explained by the fact that adrenocortical adenomas, based on histological characteristics and tumor behavior, are a highly differentiated tumor type, and repression of *CCND1* expression is thought to be a hallmark of cell differentiation.[35](#jvim12528-bib-0035){ref-type="ref"} In line with this reasoning, lower *CCND1* expression was detected in adrenocortical adenomas of humans when compared to carcinomas.[36](#jvim12528-bib-0036){ref-type="ref"} In contrast, in ACC of dogs all target genes that showed significant alteration in mRNA expression were altered in accordance with PI3K activation.

The main modes of activation of the PI3K pathway are by intracellular alterations of signaling pathway components or through receptor tyrosine kinase signaling. With regard to intracellular pathway alterations, activating mutations of *PIK3CA* and inactivating mutations of *PTEN* are well‐documented.[14](#jvim12528-bib-0014){ref-type="ref"} In this study, no amino acid‐changing mutations were detected in either *PIK3CA* or *PTEN* and no overall decreased expression of *PTEN* was detected in ATs.

With regard to receptor tyrosine kinase induced activation, 1 of the most strongly documented changes that can activate the PI3K pathway in ACC of humans, is activation of the IGF axis. Several studies have demonstrated that in ACC of humans, *IGF‐II* is the most overexpressed gene.[19](#jvim12528-bib-0019){ref-type="ref"}, [37](#jvim12528-bib-0037){ref-type="ref"} In the healthy individual, 1 of the alleles of the *IGF‐II* locus is epigenetically silenced postnatally, but in ACC genetic and epigenetic alterations in the 11p15 locus cause both alleles to be active, resulting in *IGF‐II* overexpression.[17](#jvim12528-bib-0017){ref-type="ref"} Likewise, high IGF‐II protein expression is characteristic of ACC in humans.[17](#jvim12528-bib-0017){ref-type="ref"}, [18](#jvim12528-bib-0018){ref-type="ref"} The mechanism by which high IGF‐II expression leads to activation of the PI3K pathway is by binding IGFR1, which like IGF‐II frequently shows increased expression in ACC of humans.[8](#jvim12528-bib-0008){ref-type="ref"}, [9](#jvim12528-bib-0009){ref-type="ref"} Taken together, these data suggest that in ACC of humans changes in the IGF axis could be responsible for PI3K activation. This notion is supported by studies in H295R human adrenocortical carcinoma cells, in which IGF‐II -- IGFR1 signaling results in an increase in p‐AKT.[6](#jvim12528-bib-0006){ref-type="ref"}, [7](#jvim12528-bib-0007){ref-type="ref"}, [38](#jvim12528-bib-0038){ref-type="ref"} Remarkably, this study did not identify a higher expression of either *IGF‐II* or *IGFR1* in ATs of dogs.

For *IGFBP2,* higher mRNA expression was detected in adenomas and carcinomas of dogs. The IGFBPs function as regulatory components of IGF signaling,[39](#jvim12528-bib-0039){ref-type="ref"} and some studies have indicated that high IGFBP2 expression may contribute to ACC pathogenesis. In murine Y1 AT cells, long‐term increased *IGFBP2* expression enhanced the malignant phenotype[40](#jvim12528-bib-0040){ref-type="ref"} and in *IGF‐II*‐overexpressing ACC of humans increased expression of IGFBP2 has been reported.[20](#jvim12528-bib-0020){ref-type="ref"} However, the significance of high *IGFBP2* expression in the absence of *IGF‐II* overexpression is unknown. Theoretically, high IGFBP2 expression could lead to higher IGF‐II availability and thus increase IGFR1/PI3K signaling. However, the fact that *IGFBP2* overexpression also was detected in adenomas in the absence of increased target gene expression does not support a functional role of *IGFBP2* overexpression in PI3K activation in dogs.

In contrast, *IGFBP5* showed an overall lower expression in ATs, but a 6.8‐fold higher expression in those carcinomas showing recurrence within 2.5 years after adrenalectomy. In different types of cancer in humans, *IGFBP5* overexpression has been noted as a prognostic marker. In particular, in breast cancer, high *IGFBP5* expression is associated with a shorter recurrence‐free, metastasis‐free and overall survival and *IGFBP5* overexpression in breast cancer cell lines conferred resistance to IGFR1 inhibition.[41](#jvim12528-bib-0041){ref-type="ref"} Our results therefore indicate the mRNA expression of *IGFBP5* as a relevant prognostic factor in ACC in dogs.

An alternative mechanism for receptor tyrosine kinase‐induced PI3K pathway activation is EGFR signaling. In this respect, the tendency toward higher *ERBB2* mRNA expression in ACC of dogs is interesting. ERBB2 (also known as HER2) is a receptor tyrosine kinase that lacks a ligand‐binding domain, and functions by heterodimerization with the other EGF receptors. Aberrant ERBB2 activation, for instance because of receptor overexpression, results in activation of the PI3K pathway, growth stimulation and tumorigenesis in different tumor types, of which ERBB2‐positive breast cancer is the most prominent example.[11](#jvim12528-bib-0011){ref-type="ref"}, [42](#jvim12528-bib-0042){ref-type="ref"} Different drugs targeting ERBB2 have been approved for clinical use in cancer treatment, including antibodies that inhibit heterodimerization (trastuzumab and pertuzumab[43](#jvim12528-bib-0043){ref-type="ref"}, [44](#jvim12528-bib-0044){ref-type="ref"}) and tyrosine kinase inhibitors that affect both EGFR (ie, ERBB1) and ERBB2 activity (lapatinib and afatinib[45](#jvim12528-bib-0045){ref-type="ref"}, [46](#jvim12528-bib-0046){ref-type="ref"}). Recent studies suggest that simultaneously targeting EGFR and ERBB2 further increases antitumor activity.[11](#jvim12528-bib-0011){ref-type="ref"} Based on the higher expression of *ERBB2*, this receptor might be a promising new therapeutic target in dogs with ACC, either singly or in combination with EGFR inhibition.

Aside from therapeutic targets, we also aimed to investigate the pathway components for potential new prognostic markers. In this regard, aside from *IGFBP5*,*SGK1*,*ID1* and *ID2* also are worth mentioning. The relative mRNA expression of *SGK1* was significantly lower in carcinomas. At first glance, this seems surprising, because *SGK1* is activated by PI3K signaling only at the protein level, by phosphorylation.[33](#jvim12528-bib-0033){ref-type="ref"} Recently, however, *SGK1* microdeletions and low *SGK1* mRNA expression have been reported in cortisol‐secreting ATs of humans, but not in nonsecreting or aldosterone‐secreting ATs.[47](#jvim12528-bib-0047){ref-type="ref"}, [48](#jvim12528-bib-0048){ref-type="ref"}, [49](#jvim12528-bib-0049){ref-type="ref"} Low SGK1 protein expression was found to be an independent prognostic factor for shorter overall survival.[48](#jvim12528-bib-0048){ref-type="ref"} Although this study did not identify significant differences in *SGK1* mRNA expression between dogs with and without recurrent disease, low *SGK1* expression in cortisol‐secreting carcinomas does suggest a functional role for *SGK1*. Additional studies involving SGK1 protein expression and overall survival analyses are needed to determine whether SGK1 expression might prove to be a prognostic marker in these tumors.

In the group of dogs with recurrent disease, we did find an increase in both *ID1* and *ID2* expression. This observation is in accordance with studies reporting an association between high *ID1* and *ID2* expression and poor prognosis in several different tumor types in humans.[50](#jvim12528-bib-0050){ref-type="ref"} Inhibitor of differentiation proteins are thought to keep cells in a poorly differentiated, proliferative state, and therefore a role for ID1 and 2 in the pathogenesis of malignant ATs in dogs appears likely. Based on our results, ID1 and 2 show promise as new prognostic markers for ACC in dogs. Future studies are needed to determine whether targeting IDs might also be feasible as a new therapeutic option.[51](#jvim12528-bib-0051){ref-type="ref"}, [52](#jvim12528-bib-0052){ref-type="ref"}

In conclusion, our results suggest the presence of PI3K activation in cortisol‐secreting ACC in dogs, but not in adenomas. In contrast to 1 of the most prominent features of ACC in humans, no significant alterations in *IGF‐II* or *IGFR1* expression were detected. Therefore, our results suggest that inhibition of IGF signaling is not likely to prove successful in dogs with ATs. However, we did find higher expression of *ERBB2*, providing a preclinical rationale for studying the potential of ERBB2 inhibition, as used in ERBB2‐positive breast cancer, in dogs with ACC. Finally, the lower expression of *SGK1* in carcinomas and the higher expression of *IGFBP5*,*ID1*, and *ID2* in ATs with early recurrence may represent an important step in the search for prognostic markers for cortisol‐secreting ACC in dogs.
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